In this Phase 2 study, 34% (19 of 56 patients) tre

Quote:

---

In this Phase 2 study, 34% (19 of 56 patients) treated with leronlimab compared to 50% (14 of 28 patients) treated with placebo reported at least one adverse event. A total of 19 serious adverse events (SAEs) were reported during the study. Eleven (11) SAEs were reported in 6 patients (6/28; 21.4%) receiving placebo compared to eight ( SAEs in 5 patients (5/56; 8.9%) receiving leronlimab. None of the SAEs in the leronlimab arm were deemed related to study drug administration by the investigators. Of the 84 patients treated, one patient died 33 days after enrollment due to an event unrelated to leronlimab.

---

Am I reading this correctly ??

If 19 in Lero and 14 in placebo had at least 1 AE we have 33 in total.

Then it says: "A total of 19 serious adverse events (SAEs) were reported during the study."

I am trying to run some (very imperfect) statistics but the info is not usable in that does not specify WHEN these numbers are obtained. It is baseline vs end of 14 days ??. Both @ 14 days.

At first look 11 (placebo) vs ( Leronlimab seem like a good omen as the measurements are over the means of the severity table (of these 6 patients there where more SAE than for the 5 in Leronlimab).

However need more data to approximate a number.